Liver Dysfunction Linked to Cartilage Aging Through Disrupted Selenium Delivery

A liver protein connects organ damage with joint disease

Researchers at Seoul National University and Ewha Womans University have identified a biological pathway through which liver dysfunction may accelerate osteoarthritis: reduced production of SELENOP, a protein that carries selenium through the blood to cartilage. Their findings connect population evidence of more frequent osteoarthritis among people with liver disease to experiments showing how disrupted nutrient delivery weakens cartilage cells.

The study appeared online in Cell Metabolism on September 22, 2026, and was assigned to volume 38, issue 10. Led by Professor Jin-Hong Kim of Seoul National University's Department of Biological Sciences and Professor Yi-Jun Kim of Ewha Womans University's medical school, the research examined both human population data and mice with several forms of liver injury.

Its central finding is more specific than a general association between poor metabolic health and joint problems. When the liver produced less SELENOP, cartilage received less selenium. That shortage reduced protective proteins inside cartilage cells, increased oxidative stress and promoted cellular aging. Selenium supplementation eased cartilage damage in mice, but a preventive or treatment benefit in people has not been established.

The study abstract identifies the SELENOP-ApoER2 axis as the route disrupted by liver dysfunction. This names a particular transport pathway that researchers can investigate, rather than treating liver disease and osteoarthritis as conditions that simply happen to occur together.

What the population evidence shows

The researchers began with large population datasets from within and outside South Korea. Nationwide cohorts showed a higher prevalence of osteoarthritis among people with liver disease. Prevalence describes how common a condition is in a population; it does not, by itself, establish which condition came first or prove that one caused the other.

The human analysis also found an association between daily selenium intake and osteoarthritis among people with liver disease. That observation supports investigating selenium metabolism, but it is not equivalent to a trial showing that taking selenium prevents cartilage damage. Dietary intake and a prescribed supplement are also different exposures.

The published abstract does not give cohort sizes, absolute prevalence figures or the size of the association. Without those numbers, it is not possible to state how much more common osteoarthritis was, calculate an individual patient's additional risk or identify an effective daily intake.

The distinction matters because the study combines two different kinds of evidence. The population work identifies an association in people. The animal experiments test a biological explanation under controlled conditions. Together they strengthen the case for further investigation, but they do not establish a selenium treatment for patients.

How selenium reaches cartilage

Selenium is a nutrient needed in small amounts to make certain proteins, including proteins involved in protecting cells against oxidative damage. The study focuses on how selenium reaches cartilage, not simply on how much a person consumes.

SELENOP, short for selenoprotein P, is made mainly in the liver and transports selenium through the bloodstream to other tissues. The researchers identified its connection with ApoER2, a receptor involved in cellular uptake, as a route supplying cartilage. In practical terms, the liver helps package and distribute a nutrient that cartilage cells need to maintain their defenses.

Liver dysfunction reduced SELENOP output in the animal experiments. With less of the carrier available, selenium delivery to cartilage declined. This creates a distinction between nutrient intake and nutrient distribution: consuming selenium does not necessarily mean every tissue receives an adequate supply through its usual transport route.

The findings therefore point to a failure of communication between organs. The liver injury was associated with a loss of protection in cartilage, providing an explanation for how a disorder outside the joint could contribute to joint deterioration.

Why the liver makes less SELENOP

The study describes two processes that reduced SELENOP production under hepatic stress. One was transcriptional repression, meaning liver cells produced fewer of the RNA instructions used to make the protein. The other was translational suppression, meaning those instructions were less successfully converted into protein.

The second process involved ribosome collision on SELENOP transcripts rich in selenocysteine. Ribosomes are the cellular machinery that reads RNA and assembles proteins. Selenocysteine is an amino acid containing selenium that is incorporated into selenoproteins. The researchers linked collisions in this machinery to reduced SELENOP output.

These findings locate the disruption at more than one stage of protein production. Liver stress affected both the creation of the instructions and the process of using them. The resulting fall in SELENOP offers a molecular explanation for the reduced selenium supply observed in cartilage.

The team tested acute and chronic liver injury, as well as metabolic dysfunction associated steatohepatitis, or MASH, in mice. MASH is a form of fatty liver disease involving liver inflammation and damage. Examining several types of injury extended the investigation beyond a single experimental liver condition, although the results still require testing in people.

What happens inside cartilage cells

When selenium delivery fell, cartilage cells produced fewer selenoproteins. Some of these proteins help control reactive oxygen species, chemically reactive molecules generated during normal cellular activity. When these molecules accumulate beyond the cell's ability to manage them, they can damage cellular components.

The researchers described a sequence in which reduced selenium supply weakened antioxidant protection, increased oxidative stress and promoted senescence in chondrocytes, the cells that maintain cartilage. Senescence is a state in which cells lose normal functions and can no longer support tissue health as effectively.

This is distinct from saying that a joint simply wears out through use. Cartilage depends on living cells to maintain its structure. When those cells lose protective capacity and enter senescence, the tissue becomes less able to preserve itself. In the animal models, that process accompanied worse cartilage damage and osteoarthritis.

The research also included blood analysis in investigating the link between liver function and selenium delivery. However, no blood concentration threshold or diagnostic test for identifying patients at risk was specified. The mechanism should not be mistaken for a validated screening tool.

Selenium eased joint damage in mice

The researchers then tested whether supplying selenium could compensate for the disrupted transport pathway. In mice with impaired liver function, supplementation restored cartilage cell selenoproteins and antioxidant capacity, reduced cellular senescence and eased cartilage damage and osteoarthritis progression.

The abstract specifically describes inorganic selenium supplementation as bypassing impaired SELENOP mediated delivery. This is a narrower finding than a recommendation to eat more selenium or use any supplement sold commercially. The form and conditions tested are part of the experiment and cannot be assumed to apply to every product.

The improvement occurred without the underlying liver disease disappearing. That result supports the idea that selenium delivery was a contributor to cartilage damage, rather than the joint changes merely reflecting whether liver disease had resolved.

Even so, the experiments demonstrate improvement in the animal models, not a cure for human osteoarthritis. They do not establish that damaged cartilage in people can be rebuilt, that joint pain will improve or that supplementation can replace existing care. Those are separate clinical outcomes that need direct testing.

Why the findings do not justify taking supplements

The research leaves three central clinical questions unanswered: whether selenium prevents or treats osteoarthritis in people with liver disease, what dose would provide a benefit and whether taking it for an extended period would be safe. Clinical trials are needed to address each question.

Excess selenium can be harmful. The animal results and dietary association therefore do not justify starting supplements solely on the basis of this study. A nutrient can be necessary for normal function without additional intake being beneficial for every person.

The human dietary findings also need careful interpretation. An association between intake and osteoarthritis does not establish that changing intake changes the disease. Nor does it show that every patient with liver disease has inadequate selenium in cartilage or would respond to the same intervention.

No clinical trial start date, dosing recommendation or patient selection rule was announced in the accounts of the research. The next step described by the investigators is to test whether an appropriate selenium based prevention or treatment approach can be developed for people who have both liver disease and osteoarthritis.

A broader view of osteoarthritis

The findings support a view of osteoarthritis in which joint health can be affected by metabolic changes elsewhere in the body. They do not dismiss aging, physical injury or repeated joint loading. Instead, they identify a specific additional process through which liver dysfunction could weaken cartilage protection.

Jin-Hong Kim, the Seoul National University professor who jointly led the research, described this connection in remarks translated from Korean:

This study shows that osteoarthritis can be triggered not only by problems within the joint itself, but also by the effects throughout the body of metabolic abnormalities in other organs.

Yi-Jun Kim, the Ewha Womans University professor who jointly led the study, described the proposed next stage in separate remarks translated from Korean:

We intend to test whether an appropriate selenium based prevention and treatment framework can be established for patients with osteoarthritis accompanied by liver disease.

That proposed work is narrower than recommending supplementation to everyone with osteoarthritis. It concerns a group of patients with both conditions and a mechanism that may be relevant to their joint disease. Determining who benefits will be as important as determining whether a benefit exists.

Publication and research support

The paper is titled A liver-cartilage selenium axis underlies metabolic comorbidity in osteoarthritis. Its publication record lists Cell Metabolism, volume 38, issue 10, and DOI 10.1016/j.cmet.2026.08.023. The September online publication and October issue assignment describe different stages of publication, rather than conflicting dates.

The sequence of publication and public announcements was:

• September 22, 2026: The study appeared online in Cell Metabolism.
• October 2026: The paper was assigned to volume 38, issue 10.
• October 12, 2026: The joint research team's findings were publicly described.
• October 13, 2026: Further details about the study and its support were published.

The research received support from South Korea's Ministry of Science and ICT, Ministry of Health and Welfare, Korea Drug Development Fund and Suh Kyungbae Foundation. Its strongest contribution is the connection between human population evidence and a experimentally tested nutrient transport mechanism. Its main clinical limit is that the supplementation benefit remains demonstrated in mice, not patients.

Key Points

• Population analyses found osteoarthritis was more common among people with liver disease.
• Liver stress reduced SELENOP production, disrupting selenium delivery through the SELENOP-ApoER2 pathway.
• Reduced selenium supply weakened cartilage cell antioxidant protection and promoted cellular senescence.
• Inorganic selenium supplementation reduced cartilage damage and osteoarthritis progression in mice.
• Human prevention and treatment benefits, effective doses and safety over time require clinical trials.
• Excess selenium can be harmful; the findings are not a recommendation to begin supplementation.